Faculty profile

Elise Duchesne

ResearcherUniversité du Québec à Chicoutimi

This profile is built from public research funding records (CIHR, NSERC and SSHRC) and PubMed. We have not imported them from a Université du Québec à Chicoutimi directory, so their courses may be missing. Find their university profile.

Elise Duchesne

Researcher

Health Sciences

Université du Québec à Chicoutimi

Saguenay, Quebec, Canada

Supervision signals

Has led research grants, which requires an independent research appointment. Ask their department whether they supervise graduate students.
22 publications in the last five years, latest in 2026.
Senior (last) author on 10 recent papers, a sign of leading a research group.
Principal investigator on 1 research grant (1 CIHR), most recently in 2022.

These signals come from public records, including CIHR, NSERC and SSHRC funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

Publications

Citations

h-index

Collaborators

Grants

Publications by year

Counts cover the works listed on the university profile; citation counts come from Dimensions.

Profiles and links

Search on Google Scholar

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Autosomal Recessive Spastic Ataxia Of Charlevoix-Saguenay Balance Exercise Program Hereditary Spastic Paraplegia Mobility Motor Control Movement Disorders Neurology

Latest papers

Muscle Strength, Balance, and Indoor Mobility in Oculopharyngeal Muscular Dystrophy: An Exploratory Canadian Multicenter Study.
Muscle & nerve · 2026
Large-scale proteomics profiling of peripheral blood of DM1 patients identifies biomarkers for disease severity and functional capacity.
Journal of neuromuscular diseases · 2026
What is known about muscle weakness, balance impairments and indoor mobility limitations in oculopharyngeal muscular dystrophy? A scoping review.
Journal of neuromuscular diseases · 2026 · senior author

All 31 publications

Latest funding

IMPACT, a supervised rehabilitation program for spastic ataxias: A rater-blinded, randomized controlled trial
CIHR · 2022 · Nominated PI
$638,776

All 1 grants and awards

31 publications.

Muscle Strength, Balance, and Indoor Mobility in Oculopharyngeal Muscular Dystrophy: An Exploratory Canadian Multicenter Study.

Bélair N, Brisson JD, Brais B, Rodrigue X, Lochmüller H, Hébert LJ, MacGregor J, Dennison B, Lessard I, Côté I, Duchesne E, Gagnon C

Muscle & nerve2026

DOI: 10.1002/mus.70343 PMID: 42439050

Large-scale proteomics profiling of peripheral blood of DM1 patients identifies biomarkers for disease severity and functional capacity.

van As D, Claeys T, Salz R, Haver DV, Dufour S, Deelen AV, Gloerich J, Gabriels R, Volders PJ, Dobelmann V, Gangfuss A, Ruck T, Gourdon G, Duchesne E, Gagnon C, Roos A, Gool AV, Impens F, Martens L, Lochmüller H, Schoser B, Bassez G, van Engelen BG, 't Hoen PA, OPTIMISTIC consortium, ReCognitION consortium

Journal of neuromuscular diseases2026

DOI: 10.1177/22143602251410443 PMID: 41544176

What is known about muscle weakness, balance impairments and indoor mobility limitations in oculopharyngeal muscular dystrophy? A scoping review.

Bélair N, Gagnon C, Duchesne E

Journal of neuromuscular diseases2026Senior author

DOI: 10.1177/22143602251397052 PMID: 41467981

A 12-Week Strength Training Improves Mitochondrial Respiration, H2O2 Emission and Skeletal Muscle Integrity in Women With Myotonic Dystrophy Type 1.

Marcangeli V, Girard-Côté L, Di Leo V, Roussel MP, Lawless C, Charest O, Argaw A, Dulac M, Hajj-Boutros G, Morais JA, Vincent A, Gouspillou G, Leduc-Gaudet JP, Duchesne E

Acta physiologica (Oxford, England)2025Senior author

DOI: 10.1111/apha.70135 PMID: 41241935

Bioactive lipid mediator class switching regulates myogenic cell progression and muscle regeneration.

Fabre P, Molina T, Larose J, Greffard K, Généreux-Gamache G, Deprez A, Mokhtari I, Pellerito O, Duchesne E, Dort J, Bilodeau JF, Dumont NA

Nature communications2025

DOI: 10.1038/s41467-025-60586-8 PMID: 40595516

Selection of Clinical Outcome Assessments for Trial Readiness in ARSACS - 2-year Progression and Responsiveness to Change Part 1: Disease Severity, Swallowing, Upper Limb Function, and Participation.

Lessard I, Hébert LJ, Brais B, Duchesne E, Rodrigue X, Brisson JD, Routhier F, Best K, Côté I, Gagnon C

Cerebellum (London, England)2025

DOI: 10.1007/s12311-025-01858-3 PMID: 40450178

Selection of Clinical Outcome Assessments for Trial Readiness in ARSACS - 2-year Progression and Responsiveness to Change Part 2: Mobility, Balance, and Lower Limb Coordination.

Lessard I, Duchesne E, Hébert LJ, Brais B, Rodrigue X, Routhier F, Best K, Brisson JD, Thullier F, Gaboury S, Côté I, Gagnon C

Cerebellum (London, England)2025

DOI: 10.1007/s12311-025-01849-4 PMID: 40332679

A Tailored Home-Based Training Program Improved Ataxia Severity and Participation in Adults With ARSACS.

Lessard I, Gagnon C, Tremblay M, Girard-Côté L, Côté I, Aubertin-Leheudre M, Duchesne E

Cerebellum (London, England)2025Senior author

DOI: 10.1007/s12311-025-01816-z PMID: 40095137

New Horizons in Myotonic Dystrophy Type 1: Cellular Senescence as a Therapeutic Target.

Légaré C, Berglund JA, Duchesne E, Dumont NA

BioEssays : news and reviews in molecular, cellular and developmental biology2025

DOI: 10.1002/bies.202400216 PMID: 39723693

Resistance training in women with myotonic dystrophy type 1: a multisystemic therapeutic avenue.

Girard-Côté L, Gallais B, Gagnon C, Roussel MP, Morin M, Hébert LJ, Monckton D, Leduc-Gaudet JP, Gouspillou G, Marcangeli V, Duchesne E

Neuromuscular disorders : NMD2024Senior author

DOI: 10.1016/j.nmd.2024.05.009 PMID: 38824906

Write to this professor

A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.

Applying for

Paper to mentionMention their CIHR grant from 2022

Subject: Prospective PhD student: Autosomal Recessive Spastic Ataxia Of Charlevoix-Saguenay Dear Professor Duchesne, My name is [your name], and I am a [your current degree or role] at [your institution]. I am applying for a PhD position starting in [term and year]. I read your paper "Muscle Strength, Balance, and Indoor Mobility in Oculopharyngeal Muscular Dystrophy: An Exploratory Canadian Multicenter Study." (2026), and it connects closely to my own work on [your research topic]. [One or two sentences on what you did and what you learned.] I also saw your CIHR-funded project "IMPACT, a supervised rehabilitation program for spastic ataxias: A rater-blinded, randomized controlled trial" (2022), and I would be glad to contribute to work in that direction. Are you accepting new PhD students for [term and year]? I have attached my CV and transcripts, and I would be glad to talk at a time that suits you. Thank you for your time. Kind regards, [your name]

Something wrong or missing on this profile? Suggest a correction

Elise Duchesne

Research

Latest papers

Latest funding

Muscle Strength, Balance, and Indoor Mobility in Oculopharyngeal Muscular Dystrophy: An Exploratory Canadian Multicenter Study.

Large-scale proteomics profiling of peripheral blood of DM1 patients identifies biomarkers for disease severity and functional capacity.

What is known about muscle weakness, balance impairments and indoor mobility limitations in oculopharyngeal muscular dystrophy? A scoping review.

A 12-Week Strength Training Improves Mitochondrial Respiration, H2O2 Emission and Skeletal Muscle Integrity in Women With Myotonic Dystrophy Type 1.

Bioactive lipid mediator class switching regulates myogenic cell progression and muscle regeneration.

Selection of Clinical Outcome Assessments for Trial Readiness in ARSACS - 2-year Progression and Responsiveness to Change Part 1: Disease Severity, Swallowing, Upper Limb Function, and Participation.

Selection of Clinical Outcome Assessments for Trial Readiness in ARSACS - 2-year Progression and Responsiveness to Change Part 2: Mobility, Balance, and Lower Limb Coordination.

A Tailored Home-Based Training Program Improved Ataxia Severity and Participation in Adults With ARSACS.

New Horizons in Myotonic Dystrophy Type 1: Cellular Senescence as a Therapeutic Target.

Resistance training in women with myotonic dystrophy type 1: a multisystemic therapeutic avenue.

IMPACT, a supervised rehabilitation program for spastic ataxias: A rater-blinded, randomized controlled trial

Frequent collaborators

Cynthia Gagnon

Cynthia Gagnon

Elise Duchesne

Bernard Brais

Aymeric Ravel-Chapuis

Krista Best

Bernard Brais

Gilles Gouspillou

Serge McGraw

Gregor Andelfinger

Gilles Gouspillou